Amgen’s Neulasta Ad Indirectly Targeting Biosimilars Draws US FDA Rebuke

 
• By Brenda Sandburg

Animated banner ad claiming administration of Neulasta with Amgen’s Onpro on-body injector has less risk of febrile neutropenia than administration via prefilled syringe draws untitled letter and a rare press release. FDA says claims could undermine confidence in biosimilar pegfilgrastim products.

FDA objects to Amgen's Neulasta promotion • Source: illustration/FDA

More from Marketing & Advertising

More from Compliance